Eplerenone in patients with systolic heart failure and mild symptoms - PubMed (original) (raw)
Randomized Controlled Trial
. 2011 Jan 6;364(1):11-21.
doi: 10.1056/NEJMoa1009492. Epub 2010 Nov 14.
Collaborators, Affiliations
- PMID: 21073363
- DOI: 10.1056/NEJMoa1009492
Free article
Randomized Controlled Trial
Eplerenone in patients with systolic heart failure and mild symptoms
Faiez Zannad et al. N Engl J Med. 2011.
Free article
Abstract
Background: Mineralocorticoid antagonists improve survival among patients with chronic, severe systolic heart failure and heart failure after myocardial infarction. We evaluated the effects of eplerenone in patients with chronic systolic heart failure and mild symptoms.
Methods: In this randomized, double-blind trial, we randomly assigned 2737 patients with New York Heart Association class II heart failure and an ejection fraction of no more than 35% to receive eplerenone (up to 50 mg daily) or placebo, in addition to recommended therapy. The primary outcome was a composite of death from cardiovascular causes or hospitalization for heart failure.
Results: The trial was stopped prematurely, according to prespecified rules, after a median follow-up period of 21 months. The primary outcome occurred in 18.3% of patients in the eplerenone group as compared with 25.9% in the placebo group (hazard ratio, 0.63; 95% confidence interval [CI], 0.54 to 0.74; P<0.001). A total of 12.5% of patients receiving eplerenone and 15.5% of those receiving placebo died (hazard ratio, 0.76; 95% CI, 0.62 to 0.93; P=0.008); 10.8% and 13.5%, respectively, died of cardiovascular causes (hazard ratio, 0.76; 95% CI, 0.61 to 0.94; P=0.01). Hospitalizations for heart failure and for any cause were also reduced with eplerenone. A serum potassium level exceeding 5.5 mmol per liter occurred in 11.8% of patients in the eplerenone group and 7.2% of those in the placebo group (P<0.001).
Conclusions: Eplerenone, as compared with placebo, reduced both the risk of death and the risk of hospitalization among patients with systolic heart failure and mild symptoms. (Funded by Pfizer; ClinicalTrials.gov number, NCT00232180.).
Comment in
- Aldosterone antagonists--last man standing?
Armstrong PW. Armstrong PW. N Engl J Med. 2011 Jan 6;364(1):79-80. doi: 10.1056/NEJMe1012547. Epub 2010 Nov 14. N Engl J Med. 2011. PMID: 21073364 No abstract available. - Heart failure: Placing an EMPHASIS on the mineralocorticoid receptor--benefit of eplerenone in mild HF.
King A. King A. Nat Rev Cardiol. 2011 Jan;8(1):1. doi: 10.1038/nrcardio.2010.188. Nat Rev Cardiol. 2011. PMID: 21218551 No abstract available. - Impressive results for aldosterone antagonists in mild heart failure.
Lindenfeld J. Lindenfeld J. Curr Cardiol Rep. 2011 Jun;13(3):167-9. doi: 10.1007/s11886-011-0170-9. Curr Cardiol Rep. 2011. PMID: 21318341 No abstract available. - Mineralocorticoid-receptor antagonists in heart failure: a tale of serendipity and success.
Reyentovich A, Katz SD. Reyentovich A, et al. Curr Heart Fail Rep. 2011 Jun;8(2):87-90. doi: 10.1007/s11897-011-0055-7. Curr Heart Fail Rep. 2011. PMID: 21424676 No abstract available. - Eplerenone in mild heart failure.
Dastidar AG. Dastidar AG. N Engl J Med. 2011 Apr 7;364(14):1371-2; author reply 1372. doi: 10.1056/NEJMc1101287. N Engl J Med. 2011. PMID: 21470017 No abstract available. - Eplerenone in mild heart failure.
Tomaschitz A, Pilz S, März W. Tomaschitz A, et al. N Engl J Med. 2011 Apr 7;364(14):1371; author reply 1372. doi: 10.1056/NEJMc1101287. N Engl J Med. 2011. PMID: 21470018 No abstract available. - Eplerenone in mild heart failure.
Gus M, Fuchs FD. Gus M, et al. N Engl J Med. 2011 Apr 7;364(14):1370-1; author reply 1372. doi: 10.1056/NEJMc1101287. N Engl J Med. 2011. PMID: 21470019 No abstract available. - Eplerenone in mild heart failure.
Pascual-Figal DA, Sanchez-Mas J, Januzzi JL. Pascual-Figal DA, et al. N Engl J Med. 2011 Apr 7;364(14):1370; author reply 1372. doi: 10.1056/NEJMc1101287. N Engl J Med. 2011. PMID: 21470020 No abstract available. - Eplerenon reduziert die Hospitalisations- und Mortalitätsrate bei Patienten mit milder systolischer Herzinsuffizienz.
Woitzek K. Woitzek K. Praxis (Bern 1994). 2011 Apr 13;100(8):491-2. doi: 10.1024/1661-8157/a000507. Praxis (Bern 1994). 2011. PMID: 21484715 German. No abstract available. - Eplerenone reduces risk of cardiovascular death or hospitalisation in heart failure patients with reduced ejection fraction.
Ambrosy A, Gheorghiade M. Ambrosy A, et al. Evid Based Med. 2011 Aug;16(4):121-2. doi: 10.1136/ebm1307. Epub 2011 May 10. Evid Based Med. 2011. PMID: 21558564 No abstract available. - Eplerenona en pacientes con insuficiencia cardíaca sistólica y síntomas leves.
Martín-Suñé N. Martín-Suñé N. Rev Clin Esp. 2011 May;211(5):259. doi: 10.1016/j.rce.2011.01.005. Rev Clin Esp. 2011. PMID: 21714151 Spanish. No abstract available. - More help for patients with less severe heart failure.
Bossenbroek K, Mounsey AL. Bossenbroek K, et al. J Fam Pract. 2011 Aug;60(8):482-4. J Fam Pract. 2011. PMID: 21814643 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical